吉林长龙药业2024年报

Annual Report CHARACTERISTICS OF THE GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCKEXCHANGE”) GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higherinvestment risk may be attached than other companies listed on the main board of the Stock Exchange. Prospectiveinvestors should be aware of the potential risks of investing in such companies and should make the decision toinvest only after due and careful consideration. Given that the companies listed on the GEM are generally small and mid-sized companies, there is a risk thatsecurities traded on the GEM may be more susceptible to high market volatility than securities traded on the MainBoard of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded onthe GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any losshowsoever arising from or in reliance upon the whole or any part of the contents of this report. This annual report, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited and itssubsidiaries (the “Group” and the “Directors”, respectively) collectively and individually accept full responsibility, includesparticulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange forthe purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirmthat to the best of their knowledge and belief, the information contained in this annual report is accurate and complete in allmaterial respects and not misleading or deceptive, and there are no other matters the omission of which would make anystatement herein or this annual report misleading. 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位，乃為中小型公司提供的市場，此等公司相比起其他在聯交所主板上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並表明不會就本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本年度報告乃遵照聯交所GEM證券上市規則的規定而提供有關吉林省輝南長龍生化藥業股份有限公司及其附屬公司（「本集團」）的資料，本公司各董事（「董事」）願共同及個別對此負全責。董事經作出一切合理查詢後確認，就彼等所知及所信，本年度報告所載資料在所有重大方面均準確完整及並無誤導或欺詐成分，及概無遺漏其他事宜，致使本年度報告中任何聲明或本年度報告存在誤導成分。 CONTENTS目錄 3–4Corporate Information公司資料5–7Chairman’s Statement主席報告8–16Management Discussion and Analysis管理層討論及分析17–21Biographical Details of Directors and Senior Management董事及高級管理層簡歷22–30Report of the Directors董事會報告書31–38Corporate Governance Report企業管治報告39Report of the Supervisory Committee監事會報告書40–45Independent Auditor’s Report獨立核數師報告書46Consolidated Statement of Profit or Loss andOther Comprehensive Income綜合損益及其他全面收益表47–48Consolidated Statement of Financial Position綜合財務狀況表49Consolidated Statement of Changes in Equity綜合權益變動表50–51Consolidated Statement of Cash Flows綜合現金流量表52–123Notes to the Consolidated Financial Statements綜合財務報表附註124Five-Year Financial Summary五年財務摘要 CORPORATE INFORMATION公司資料 董事會執行董事張弘先生（主席）張曉光先生趙寶剛先生吳國文先生張翼先生徐向夫先生 BOARD OF DIRECTORS Executive DirectorsMr. Zhang Hong(Chairman)Mr. Zhang Xiao GuangMr. Zhao Bao GangMr. Wu Guo WenMr. Zhang YiMr. Xu Xiang Fu 獨立非執行董事高其品先生田傑女士白君貴先生 Independent Non-Executive DirectorsMr. Gao Qi PinMs. Tian JieMr. Bai Jun Gui 監事王英旭先生鄢禮玉先生喬曉春女士 SUPERVISORSMr. Wang Ying XuMr. Yan Li YuMs. Qiao Xiao Chun 監察主任張弘先生 COMPLIANCE OFFICERMr. Zhang Hong 授權代表張弘先生趙寶剛先生 AUTHORIZED REPRESENTATIVESMr. Zhang HongMr. Zhao Bao Gang 核數師栢淳會計師事務所有限公司（前稱「上會栢誠會計師事務所有限公司」）執業會計師香港 AUDITORSPrism Hong Kong Limited(formerly named “Prism Hong Kong and Shanghai Limited”)Certified Public AccountantsHong Kong 審核委員會白君貴先生田傑女士高其品先生 AUDIT COMMITTEEMr. Bai Jun GuiMs. Tian JieMr. Gao Qi Pin 薪酬委員會白君貴先生田傑女士高其品先生張弘先生 REMUNERATION COMMITTEE Mr. Bai Jun GuiMs. Tian JieMr. Gao Qi PinMr. Zhang Hong CORPORATE INFORMATION公司資料 公司秘書兼合資格會計師 COMPANY SECRETARY ANDQUALIFIED ACCOUNTANTMr. Mok Sai Cheong Mark,CPA, FCCA 莫世昌先生，CPA, FCCA 提名委員會白君貴先生田傑女士高其品先生張曉光先生 NOMINATION COMMITTEEMr. Bai Jun GuiMs. Tian JieMr. Gao Qi PinMr. Zhang Xiao Guang H股過戶登記處 H SHARE SHARE REGISTRAR ANDTRANSFER OFFICE 香港證券登記有限公司香港皇后大道東183號合和中心17M樓 Hong Kong Registrars Limited17M FloorHopewell Centre183 Queen’s Road EastHong Kong 主要往來銀行中國工商銀行輝南縣支行中國吉林省通化市 PRINCIPAL BANKERIndustrial and Commercial Bank of ChinaHuinan County BranchTonghuaJilin ProvincePRC 香港主要營業地點香港九龍旺角彌敦道625及639號雅蘭中心辦公樓二期11樓1101–2室 PRINCIPAL PLACE OF BUSINESS IN HONG KONGRoom 1101–2, 11/FOffice Tower Two, Grand Plaza625 & 639 Nathan RoadMong Kok, KowloonHong Kong 股份代號8049 STOCK CODE8049 法定地址中國吉林省通化市輝南縣朝陽鎮北山街31號 LEGAL ADDRESS31 Beishan StreetChaoyang TownHuinan CountyTonghuaJilin ProvincePRC 網址http://www.jlchanglong.com WEBSITE ADDRESShttp://www.jlchanglong.com CHAIRMAN’S STATEMENT主席報告 本人謹代表董事會（「董事會」）欣然提呈吉林省輝南長龍生化藥業股份有限公司（「本公司」）及其附屬公司（合稱「本集團」）截至二零二四年十二月三十一日止年度之經審核綜合業績。